These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16892366)

  • 1. An accurate and interpretable bayesian classification model for prediction of HERG liability.
    Sun H
    ChemMedChem; 2006 Mar; 1(3):315-22. PubMed ID: 16892366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of hERG potassium channel blockage.
    Wang S; Li Y; Wang J; Chen L; Zhang L; Yu H; Hou T
    Mol Pharm; 2012 Apr; 9(4):996-1010. PubMed ID: 22380484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Support vector machines classification of hERG liabilities based on atom types.
    Jia L; Sun H
    Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing.
    Sun H
    J Med Chem; 2005 Jun; 48(12):4031-9. PubMed ID: 15943476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent developments in computational prediction of HERG blockage.
    Wang S; Li Y; Xu L; Li D; Hou T
    Curr Top Med Chem; 2013; 13(11):1317-26. PubMed ID: 23675938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hERG classification model based on a combination of support vector machine method and GRIND descriptors.
    Li Q; Jørgensen FS; Oprea T; Brunak S; Taboureau O
    Mol Pharm; 2008; 5(1):117-27. PubMed ID: 18197627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches.
    Wang S; Sun H; Liu H; Li D; Li Y; Hou T
    Mol Pharm; 2016 Aug; 13(8):2855-66. PubMed ID: 27379394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of hERG potassium channel blockade by antipsychotics.
    Silvestre JS; Prous JR
    Methods Find Exp Clin Pharmacol; 2007 Sep; 29(7):457-65. PubMed ID: 17982510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity.
    Anwar-Mohamed A; Barakat KH; Bhat R; Noskov SY; Tyrrell DL; Tuszynski JA; Houghton M
    Toxicol Lett; 2014 Nov; 230(3):382-92. PubMed ID: 25127758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico classification of HERG channel blockers: a knowledge-based strategy.
    Dubus E; Ijjaali I; Petitet F; Michel A
    ChemMedChem; 2006 Jun; 1(6):622-30. PubMed ID: 16892402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine-learning technique, QSAR and molecular dynamics for hERG-drug interactions.
    Das NR; Sharma T; Toropov AA; Toropova AP; Tripathi MK; Achary PGR
    J Biomol Struct Dyn; 2023; 41(23):13766-13791. PubMed ID: 37021352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of hERG potassium channel blockage using ensemble learning methods and molecular fingerprints.
    Liu M; Zhang L; Li S; Yang T; Liu L; Zhao J; Liu H
    Toxicol Lett; 2020 Oct; 332():88-96. PubMed ID: 32629073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacologically validated, high-capacity, functional thallium flux assay for the human Ether-à-go-go related gene potassium channel.
    Schmalhofer WA; Swensen AM; Thomas BS; Felix JP; Haedo RJ; Solly K; Kiss L; Kaczorowski GJ; Garcia ML
    Assay Drug Dev Technol; 2010 Dec; 8(6):714-26. PubMed ID: 21158686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
    Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indexing molecules for their hERG liability.
    Rayan A; Falah M; Raiyn J; Da'adoosh B; Kadan S; Zaid H; Goldblum A
    Eur J Med Chem; 2013 Jul; 65():304-14. PubMed ID: 23727540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
    Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
    Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.